Advanced Multicenter Research (AMR) is a Web-based information technology infrastructure, fully integrated to manage every single part of a clinical trial, but with 'independent' and 'customizable' components to wholly meet each team's requirements. The AIEOP group utilizes AMR for the management and analyses of the majority of the expected nationwide oncology cases and the most common primary immunodeficiencies, and for all the AIEOP protocols, studies and registries centralized at the AIEOP Operation Office. Standard for data quality control is applied to each AIEOP database according to the AMR standard procedures. The AMR AIEOP network represents a model of Information Based Medicine, a crucial tool for well-informed pediatricians, essential to guarantee better childcare in a setting of patients such as children with cancer.
Introduction
To improve the level of health services provided to children affected by tumors in Italy, the Italian Association for Paediatric Hematology Oncology (AIEOP), founded in 1975, set the main aims of promoting a scientific activity on pediatric hematology and oncology and activating multicenter diagnostic and therapeutic protocols for childhood tumors.
This first aim was reached, as documented by an overall survival probability of 0.68 at 15 years (Table 1) , with an evident increment over time: a 5-year survival probability of 0.68 vs 0.74 for cases enrolled between 1989 and 1993 and between 1994 and 1998, respectively.
In 1976, the first multicenter protocol for diagnosis and treatment of childhood acute lymphoblastic leukemia (ALL) was opened to enrolment, initially by few Italian centers. This pioneer experience on a small number of cases also revealed the need to manage the huge amount of data collected for each patient enrolled.
This problem became more and more critical with the increase in the number of patients enrolled, in the subsequent generations of protocols for ALL and other tumors, by more and more AIEOP centers.
The first step toward the optimization of the information management system was represented by the AIEOP choice of shared general use informatic facilities rather than dedicated ones to minimize data quality-related issues.
The design and development of disease-oriented electronic databases for patients' data collection of AIEOP protocols were possible, thanks to the collaboration of Interuniversity Computing Center (CINECA) started in 1985.
This necessarily led to the creation of the AIEOP Operation Office devoted to the management and control of information flows from protocol design to data analysis.
Since 1989, the centers belonging to the AIEOP network adopted a common centralized system for registration of childhood cancer, known as form Mod.1.01, with the main aims of setting up a hospital-based national Registry of pediatric cancer, monitoring protocol enrolments and intra-extra regional migration of pediatric patients affected by cancer. 1 Since then, the Mod.1.01 form has become the standard for the registration of each new child affected by tumor diagnosed or treated in any AIEOP center, whether entered or not in any official protocol.
These information-based tools show that 82% of the expected cases were observed by at least one of the AIEOP network centers. This population was enrolled in a first-line formal study protocol in 80% of cases, with a constant increment over time. The favorable impact of this policy, considered as a direct effect of networking, turned out in a higher 10-year survival probability for patients enrolled and treated according to one of the AIEOP diagnostic and therapeutic protocols vs those treated according to other therapeutic indications (0.72 vs 0.58).
In terms of quality of life (QL) indicators, the AIEOP model impacted favorably on the phenomenon of patients and their families migrating for diagnosis and/or treatment. Migration still involves 25% of cases and continues to prevail among patients living in southern Italy (37%) and those affected by solid tumors (35%). Nevertheless, the AIEOP network has reduced extraregional migration constantly overtime from 27.6 to 23.6% for cases enrolled between 1989 and 1994 and between 1995 and 2000, respectively (Po0.01).
Furthermore, from 1999, Mod.1.01 has been adopted for registration of patients (adults and children) affected by primary immunodeficiencies diagnosed and/or treated by AIEOP centers and also by other Italian institutions with expertise in clinical immunology, which adhered to an AIEOP protocol. 2 Centers participating in the AIEOP-Bone Marrow Transplant (BMT) Group, performing hematopoietic stem cell transplants (HSCT) in children, are required to report annually all consecutive transplants to the AIEOP-BMT Registry; similarly, the Mod.1.01 form has been also adopted to register transplanted cases affected by a disease other than a tumor or primary immunodeficiency. 3 Mod.1.01 offers training courses on the AIEOP methodology of data collection, such as the need for information mixing between AIEOP disease-oriented databases and AIEOP-BMT Registry, and the randomization process required by some protocols that imply the use of a methodology that meets both good clinical practice guidelines and proper informatics tools.
We have thus far seen the reasons why AIEOP has adopted a web-based centralized general system to manage information (patients and process data) derived from clinical and epidemiological studies.
This computer-based customer-designable tool allows the management of the whole flow of information from data entry, through clinical trial conduction process in terms of randomization and quality control, to monitoring and online data analysis, according to the Advanced Multicenter Research (AMR) method.
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Advanced multicenter research
Advanced Multicenter Research is a web-based information technology infrastructure, fully integrated to manage every single part of the clinical trial, but with 'independent' and 'customizable' components to wholly meet each team's requirements.
This technology was developed by CINECA on the AIEOP model since 1985. The last Hypernet version, released in 2000, meets both the ICHGCP guidelines and the FDA 8 21 CFR 11-FDA 1678 Guidance, as well as the European regulations and validation process on electronic records and signature requirements. [6] [7] [8] The AMR entails creating an integrated data management system with different user profiles, such as institution, data manager, coordinator and laboratory, and is ready to be opened to external users.
Each center enters the patients' data online, using electronic case report forms. Input is monitored by upfront filters and quality checks, with warning or blocking effects. The center can have access to the monitoring reports of its own patients and may have restricted access to some of the general data regarding the entire patient population.
The system has been implemented under Oracle and is protected by Ianus technology, through the capability of an Extranet.
All these technical and logical features make this method comply with national and international guidelines for the handling of health data.
The AIEOP group utilizes AMR for the management and analyses of the majority of the expected nationwide oncology cases and the most common primary immunodeficiencies, and for all the AIEOP protocols, studies and registries centralized at the AIEOP Operation Office. Nowadays, 12 databases (Mod.1.01, BMT Registry, and 10 disease-oriented databases: four for malignancies-ALL, acute myeloid leukemia, Hodgkin's disease, Ewing's sarcoma-along with six for primary immunodeficiencies: X-linked agammaglobulinemia, autosomal recessive agammaglobulinemia, chronic granulomatous disease, common variable immunodeficiency, transient hypogammaglobulinemia, Wiskott-Aldrich syndrome) have been set up, containing data from 52 multicenter protocols for a total number of 30 267 cases up to 28 September 2006, and registered by 52 centers belonging to AIEOP and 19 centers participating to primary immunodeficiencies protocols ( Figure 1) .
All databases are structured in a hierarchical-relational way, providing for a patient-oriented table containing registration data, patient's diagnosis, treatment, side effects, follow-up (and death) and information about any possible patient's transfer to another center.
The follow-up table includes a general section, common to all AIEOP databases, and a specific section for each disease. For each database, distinct access profiles are assigned to the Study Coordinator, Operation Office, Statistician, Data Review Committee and to each Center's Principal Investigator, respectively.
AIEOP Web-based AMR
Patient's registration Each new patient referring to an AIEOP center with a diagnosis of tumor, or affected by primary immuno- deficiency and referring to a center belonging to AIEOP or participating to primary immunodeficiencies protocols, and any patients submitted to HSCT in a center belonging to the AIEOP-BMT Group is registered through this system in the AIEOP Mod.1.01 Registry database. At the end of the registration phase, the system automatically assigns to each new patient a unique AIEOP patient number, which is recorded in the general AIEOP database, to be able to identify that patient in any of the participating centers he/she may choose to refer to ( Figure 1 also or only in the BMT Registry is provided for by the AIEOP system.
Protocol format for data entry
For each disease-oriented database, specific electronic forms concerning diagnosis, treatment, side effects, toxicity and follow-up are provided. Differently, the AIEOP-BMT Registry includes forms regarding pre-HSCT clinical history, HSCT procedure, donor characteristics and HSCT complications and follow-up.
Other options
Many other features are available, as the AIEOP system is tailored to each specific database requirement. For example, the ALL database provides for a double randomization of cases entering protocol AIEOP LLA 2000; furthermore, referral laboratories provide for compilation of immunology and molecular analysis fields in the ALL database and data entry of Bruton tyrosine kinase gene sequence analysis of each patient, his/her mother and other female collaterals in the X-linked agammaglobulinemia electronic diagnosis form.
Data quality control
The control of data quality is one of the most important aspects of quality management. Standard for data quality control is applied to each AIEOP DB according to AMR standard procedures. Specific data quality protocol procedures are specifically defined and applied before analysis and data extraction. 
Data transfer
Data management and analysis
Data handling, such as modifying or deleting functions, for information stored in each database are available only to the protocol Data Review Committee through the AIEOP Operation Office staff. The center's users have full access only to information belonging to their own patients; nevertheless, they have the opportunity to obtain restricted reports on the whole population as defined by the Study Coordinator.
Conclusions
The application of advances information technology (informatics and networking) to high standard clinical and basic research protocols organized to integrate emerging discoveries in science and medicine is giving rise to a new discipline denominated Information Based Medicine. 9 This improves the existing medical practices with knowledge generated from the integration of diverse biomedical and clinical data. The final objective of Information Based Medicine is to pull together and organize the information so that doctors/researchers can have better access to more data with the final goal of improving diagnoses, treatments and QL, as well as the development of drugs that are more specific for both patients and diseases. The AMR AIEOP network represents a model of Information Based Medicine, a crucial tool for well-informed pediatricians, essential to guarantee better childcare in a setting of patients such as children with cancer.
